Drugs / 4-Factor Prothrombin Complex Concentrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04543383 | Jul 2020 → Jun 2023 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03064035 | Apr 2017 → Apr 2019 | hemorrhagic disease | HealthPartners Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-Factor Prothrombin Complex Concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04543383 ↗ |
| Known as | 4F-PCC | “4-Factor Prothrombin Complex Concentrate (4F-PCC)” NCT04543383 ↗1“4-factor prothrombin complex concentrate (4FPCC)” NCT03064035 ↗ |
| Modality | Protein / enzyme biologic | “4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal” NCT03064035 ↗ |
| Route | Intravenous | “4F-PCC will be administered intravenously.” NCT04543383 ↗ |